Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
Returns on capital
Jade Biosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.3%
avg -96.5%
ROIC
-34.1%
avg -93.7%
ROA
-36.4%
avg -72.9%
Analysis
ROIC is currently the strongest return metric at -34.1% versus its period average of -93.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Tom Frohlich | President, CEO & Director | USD 1.02M | 50 | 86.33K | 0.26% |
Andrew James King | President of Research & Development | USD 765.9K | 46 | 247.50K | 0.76% |
Bradford D. Dahms | CFO & Treasurer | USD 350.05K | 37 | 37.81K | 0.12% |
Jonathan Quick | Senior Vice President of Finance | — | — | 83.80K | 0.26% |
Amy Sullivan | Senior Vice President of Development Operations | — | — | — | — |
Lori Stewart | Senior Vice President of People | — | — | — | — |
Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | — | — | — | — |
Valerie Fauvelle | Senior Vice President of Regulatory & Quality | — | — | — | — |
Edward R. Conner | Chief Medical Officer | — | 53 | — | — |
Elizabeth Balta | Chief Legal Officer & Corporate Secretary | — | 55 | 28.13K | 0.09% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Jade Biosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about JBIO's management, answered from reported figures.
Who manages JBIO?
Jade Biosciences, Inc. (JBIO) lists 10 active executives. The top listed executive is Jonathan Quick, Senior Vice President of Finance.
Are JBIO insiders buying or selling?
Recent insider activity shows net buying of $38.34M.
Continue the stock analysis
Jump to another research area for this company.